Biogen's most recent trend suggests a bearish bias. One trading opportunity on Biogen is a Bear Call Spread using a strike $300.00 short call and a strike $310.00 long call offers a potential 28.21% return on risk over the next 18 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $300.00 by expiration. The full premium credit of $2.20 would be kept by the premium seller. The risk of $7.80 would be incurred if the stock rose above the $310.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Biogen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Biogen is bearish.
The RSI indicator is at 52.29 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Biogen
BIOGEN IDEC INC. Financials
Tue, 29 Apr 2014 17:04:09 GMT
Biogen to present two-year data from Plegridy Phase 3 study at AAN meeting
Tue, 29 Apr 2014 11:41:32 GMT
7:31 am Biogen Idec to present new two-year data from the PLEGRIDY (Peginterferon Beta-1a) Phase 3 ADVANCE study at AAN annual meeting; two-year data consistent with positive efficacy and safety observed in year one
Tue, 29 Apr 2014 11:31:00 GMT
Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting
Tue, 29 Apr 2014 11:30:00 GMT
Business Wire – Today Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY™ in people with relapsing forms of multiple sclerosis .
Look beyond Silicon Valley for lasting innovation
Tue, 29 Apr 2014 11:00:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook